Latest News and Press Releases
Want to stay updated on the latest news?
-
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
-
Richland WA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive...